Skip to content
DataLookout
Menu

NICE-40NCT04981899

PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 1/2 → Phase 2 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 14 words
    • Trial completed
    • Final enrollment: 37 participants (planned 30)
    • Study sites: 3 to 5
    • Secondary endpoints: 5 to 6
    • Study title shortened, about 17 words
  2. Minor Site details revised at 1 of 3 sitesv4
  3. Notable Primary completion date changed from estimate of Oct 1, 2023 to May 1, 2026v3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Oct 1, 2024 to Sep 15, 2026
    • Secondary endpoints: 3 to 5
    • Site details revised at 3 of 3 sites
  4. Notable Primary completion date: Mar 1, 2023 to Oct 1, 2023
    • Study completion date: Mar 1, 2023 to Oct 1, 2024
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Response Rate (ORR)
Timeframe: 12 months

Secondary (6)

Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03
Duration of Response (DOR)
Overall Survival (OS)
Progression-Free Survival (PFS)
Progression-Free Survival Rate (Post Autologous Transplant)
Show 1 moreShow less
Overall Survival (Post Autologous Transplant)

Arms and interventions

Main armExperimental

Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT. Patients with \<CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment.

Drugs: Nivolumab, Ifosfamide, Carboplatin, Etoposide

Sites

5 sites in 1 country